Stryker Corporation reports developments as a global medical technology company serving MedSurg, Neurotechnology and Orthopaedics markets. Company news commonly covers operating results, organic sales trends, segment performance, dividends, shareholder-meeting activity and executive finance or investor-relations appointments.
Stryker updates also address portfolio expansion across medical devices, implants, instruments, operating-room equipment, neurotechnology and vascular solutions. Recent corporate activity includes the completed acquisition of Amplitude Vascular Systems, adding an intravascular lithotripsy platform for peripheral arterial disease to Stryker's peripheral vascular portfolio.
Stryker (NYSE:SYK) announced a quarterly dividend of $0.695 per share, payable on July 29, 2022, to shareholders of record on June 30, 2022. This marks a 10.3% increase compared to the previous year while remaining unchanged from the last quarter. Stryker is a leading medical technology company that significantly contributes to healthcare improvements worldwide, positively impacting over 100 million patients annually through its comprehensive range of innovative medical products and services.
Stryker announced the successful results of a two-year multicenter trial comparing its InSpace implant to partial repair for massive irreparable rotator cuff tears (MIRCTs), published in the Journal of Bone and Joint Surgery. The study involved 184 patients and demonstrated that InSpace provides effective treatment with early functional recovery, pain relief, and shorter surgical times. This biodegradable implant offers a less invasive alternative for patients, addressing common shoulder dysfunctions, and is positioned as a significant innovation in surgical options for MIRCTs.
Stryker (NYSE:SYK) will take part in the Bank of America Securities 2022 Health Care Conference on May 11, 2022, at 11:00 a.m. Eastern Time. The company will be represented by Andy Pierce, Group President of MedSurg and Neurotechnology, and Preston Wells, Vice President of Investor Relations. Interested parties can access a simultaneous webcast of the presentation on Stryker's website, where it will also be archived for later viewing. Stryker is renowned for its innovative medical technology aimed at enhancing healthcare outcomes.
Stryker reported a strong first quarter of 2022, with net sales increasing 8.1% to $4.3 billion and organic net sales rising 9.2%. The reported EPS increased 6.3% to $0.84, while the adjusted EPS rose 2.1% to $1.97. Despite these positive results, the company acknowledged ongoing challenges from COVID-19 and supply chain issues. For the full year, Stryker anticipates organic net sales growth at the higher end of the 6% to 8% guidance range and adjusted EPS at the lower end of $9.60 to $10.
Stryker (NYSE:SYK) will hold a conference call on April 28, 2022, at 4:30 p.m. ET to discuss its operating results for Q1 2022, following the release of final results at 4:05 p.m. on the same day. Interested participants can register for the call here. A webcast will be available on Stryker's Investor Relations page, with a replay accessible after the call. Stryker is a leading medical technology company focused on improving healthcare outcomes.
Stryker (NYSE:SYK) has scheduled its 2022 Annual Meeting of Shareholders for May 4, 2022, at 9:30 a.m. ET. The meeting will be held virtually, with details available on the Investor Relations page of the company's website. Shareholders can listen in by calling specified numbers. A recording of the meeting will be accessible starting May 5, 2022, until the filing of the definitive proxy statement for the 2023 meeting. Stryker is known for its innovative medical technology solutions across various specialties, aimed at improving healthcare outcomes.
Vocera Communications, Inc. announced a change following its acquisition by Stryker Corporation (NYSE: SYK). As of February 23, 2022, a Fundamental Change has occurred under the indentures governing Vocera’s 1.50% Convertible Senior Notes due 2023 and 0.50% Convertible Senior Notes due 2026. Noteholders can repurchase their Notes for cash at a price of 100% of the principal amount and accrued interest by March 25, 2022. Additionally, noteholders can convert their Notes at an increased rate until March 25, 2022. The Paying Agent is U.S. Bank Trust Company.
Stryker has successfully completed its acquisition of Vocera Communications for $79.25 per share, finalizing the tender offer that expired on February 22, 2022. Approximately 85% of Vocera's outstanding shares were tendered. This acquisition will enhance Stryker's digital healthcare offerings, promoting safer patient care. The financial impact on Stryker's net earnings per diluted share is projected to be neutral in 2022. Following the acquisition, Vocera will become a wholly owned subsidiary and will be delisted from the NYSE.
Stryker (NYSE:SYK) will participate in the Cowen 42nd Annual Health Care Conference on March 7, 2022. Vice President and CFO Glenn Boehnlein will present virtually at 10:30 a.m. Eastern Time. Interested parties can access a live webcast and replay on Stryker's official website, which will be archived for future viewing. Stryker, a leader in medical technology, aims to enhance healthcare through innovative products and services in diverse areas, including Medical and Surgical, Neurotechnology, Orthopaedics, and Spine.
Stryker (NYSE:SYK) has declared a quarterly dividend of $0.695 per share, set to be paid on April 29, 2022, to shareholders recorded as of March 31, 2022. This marks a 10.3% increase compared to the previous year and remains unchanged from the last quarter. As a leader in medical technology, Stryker is committed to enhancing healthcare through innovative products and services, improving patient and hospital outcomes. For further details, visit www.stryker.com.